ClinicalTrials.gg
CompletedNCT02953132Updated May 18, 2017

A Clinical Study to See How the Study Drug MT-4129 is Taken up by the Body in Healthy Volunteers

A Phase 1 interventional study of MT-4129 and Placebo in Healthy, sponsored by Mitsubishi Tanabe Pharma Corporation. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-18.

Sponsored by Mitsubishi Tanabe Pharma Corporation · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the safety and tolerability of ascending single and multiple oral doses of MT-4129 in healthy subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Mitsubishi Tanabe Pharma Corporation is the lead sponsor of 40 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy and free from illness or disease
  • Male or female subjects aged 18 to 55 years or elderly male subjects aged ≥65
  • A body weight of ≥60 kg for males and ≥50 kg for females, and a ranging from 18 to 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Participated in more than three clinical studies involving administration of an IMP in the previous year, or any study within 12 weeks
  • endocrine, thyroid, hepatic, respiratory, gastro intestinal, neurological, renal, cardiovascular disease, or history of any significant psychiatric/psychotic illness disorder
  • Clinically relevant abnormal medical history, physical findings or laboratory values
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Single ascending dose, MT-4129 or Placebo

    Drug: MT-4129 · Drug: Placebo

  • Experimental
    Multiple ascending dose, MT-4129 or Placebo

    Drug: MT-4129 · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as measured by incidence and severity of adverse events

    Time frame: Up to Day 14

  2. Safety and Tolerability as measured by vital signs

    Time frame: Up to Day 14

  3. Safety and Tolerability as measured by ECG

    Time frame: Up to Day 14

  4. Safety and Tolerability as measured by clinical laboratory assessments

    Time frame: Up to Day 14

  5. Safety and Tolerability as measured by Hormone assessments

    Time frame: Up to Day 10

  6. Safety and Tolerability as measured by physical examination

    Time frame: Up to Day 14

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) of MT-4129

    Time frame: Up to Day 10

  2. Measured time of maximum observed plasma concentration (tmax) of MT-4129

    Time frame: Up to Day 10

  3. Apparent terminal elimination half-life (t1/2) of MT-4129

    Time frame: Up to Day 10

  4. AUC from time zero to 24 hours post-dose (AUC0-24) of MT-4129

    Time frame: Up to Day 8

  5. AUC from time zero to 48 hours post-dose (AUC0-48) of MT-4129

    Time frame: Up to Day 9

  6. AUC from time zero to 72 hours post-dose (AUC0-72) of MT-4129

    Time frame: Up to Day 10

  7. AUC from time zero to infinity (AUC0-∞) of MT-4129

    Time frame: Up to Day 10

  8. AUC from time zero to the last measurable concentration (AUC0-last) of MT-4129

    Time frame: Up to Day 10

  9. AUC over the dosing interval (AUC0-t) of MT-4129

    Time frame: Up to Day 10

  10. Terminal elimination rate constant (Kel) of MT-4129

    Time frame: Up to Day 10

  11. Mean residence time (MRT) of MT-4129

    Time frame: Up to Day 10

  12. Apparent volume of distribution during terminal phase after oral administration (Vz/F) of MT-4129

    Time frame: Up to Day 10

  13. Apparent volume of distribution at steady state (Vss/F) of MT-4129

    Time frame: Up to Day 10

  14. Apparent oral clearance (CL/F) of MT-4129

    Time frame: Up to Day 10

  15. Urinary excreted amount of test compound (Ae) of MT-4129

    Time frame: Up to Day 10

  16. Urinary excreted amount of test compound expressed as a percentage of the dose administered (Ae%) of MT-4129

    Time frame: Up to Day 10

  17. Renal clearance (CLR) of MT-4129

    Time frame: Up to Day 10

  18. Plasma aldosterone

    Time frame: Up to Day 10

  19. Serum cortisol

    Time frame: Up to Day 10

  20. Plasma steroid hormones

    Time frame: Up to Day 10

  21. Urinary aldosterone

    Time frame: Up to Day 10

  22. Urinary cortisol

    Time frame: Up to Day 10

  23. Urinary sodium

    Time frame: Up to Day 10

  24. Urine potassium

    Time frame: Up to Day 10

07

Study locations

1 site
  • Pharmaceutical Research Associates (PRA) Health Sciences
    City Name, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2016
First posted
Nov 2, 2016
Start
Nov 2016
Primary completionActual
May 2017
CompletionActual
May 2017
Last update
May 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02953132
Responsible party
Sponsor
First posted
Nov 2, 2016
Start date
Nov 2016
Primary completion
May 2017
Completion
May 2017
Last update
May 18, 2017

Study contacts

General Manager
study director · Mitsubishi Tanabe Pharma Corporation
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorundrostat hydrobromide

Start the discussion